WILMINGTON, MA--(Marketwire - Feb 28, 2012) - Implant Sciences Corporation (OTCQB: [ IMSC ]) (PINKSHEETS: [ IMSC ]), a high technology supplier of systems and sensors for homeland security markets, announced today it sold seven Quantum Sniffer™ QS-H150 portable explosives trace detectors to an airport in China. Implant Sciences continues to penetrate the China security market, having sold several million dollars worth of its QS-H150 there since 2008, to a large number of customers, including the Civil Aviation Administration of China.

According to the China Daily, between 2011 and 2015 China is planning to expand as many as 91 of its existing 175 airports, while adding 56 new and potentially relocating 16 others. Implant Sciences' distribution channels are well positioned to share in this growth, as well as growth in the rail and subway markets. This most-recent sale was made through the Company's Beijing-based distributor Beijing JingAnLanDun Science and Technology Development Co., Ltd.

"Aviation security continues to be an important market for us in China," stated Implant Sciences' President and CEO Glenn D. Bolduc. "The QS-H150's quality, functionality, performance, and low cost-of-use consistently win contracts even when going up against companies that are larger than us with far greater resources. We also see significant opportunity in the aviation security market with our newest product offering, the QS-B220."

About the Quantum Sniffer™ QS-H150
The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220
The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences
Implant Sciences develops, manufactures, and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed innovative proprietary technologies used in its explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences products have been deployed in a wide range of security environments including airports, subways, railways, cargo facilities, nuclear power plants, police departments, military units, government buildings, and financial institutions. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ].

Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.